Estrogen Management Study

Have you been on or are you considering hormone replacement therapy?

Did you know that sudden estrogen withdrawal, as experienced after removal of the ovaries or when hormone replacement therapy is discontinued abruptly is associated with increased cancer risk for women with the KRAS-variant?  


If you are on or considering hormone replacement therapy, you are eligible for our studies as well as KRAS-variant testing. If you would like to join a study, please complete the eligibility survey.

Take The Eligibility Survey

Stay up-to-date on the latest stories, events, news & research through our e-newsletter.

What we know about the KRAS-variant:

  • Found in 6-10% of the population, and up to 25% of newly diagnosed breast, ovarian and lung cancer patients.
  • Predicts sensitivity and resistance to several standard-of-care cancer treatments/therapies.
  • Explains the genetic cause of cancer for up to 50% of Hereditary Breast and Ovarian Cancer (HBOC) families with no other known genetic markers.
  • Associated with advanced endometriosis and infertility.
  • Associated primarily with post-menopausal cancer development, enabling the opportunity for appropriate prevention.

The KRAS-variant is a recently discovered, novel, inherited genetic marker associated with cancer. The latest research indicates the KRAS-variant shows great potential to guide disease prevention and management across cancer types through its unique interactions with hormones and cancer therapies.


We encourage you to see if you are eligible to join a MiraKind study to help us discover meaningful ways to better treat patients with genetic mutations. If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study.  If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.

Take the Survey

MiraKind’s pipeline of planned and ongoing research studies are designed to protect the health of individuals with the KRAS-variant and to help answer the most pressing questions about cancer.

Research questions include:

  • What are the best cancer management strategies for KRAS-variant cancer patients?
  • What environmental factors, hormone exposures, medicines, or other lifestyle factors can influence cancer risk for individuals with the KRAS-variant?
  • How can cancer survivors who are positive for the KRAS-variant protect themselves from secondary cancers?
  • How can we prevent cancers associated with the KRAS-variant for family members who are positive but have never been diagnosed with cancer?
  • What is the best estrogen management strategy for women with the KRAS-variant?
arrow up to top